Skip to main content
Zelluna ASA logo

Zelluna ASA — Investor Relations & Filings

Ticker · ULTI ISIN · NO0010851603 LEI · 254900B4VALJZR9TL744 OL Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2020-11-11 AGM Information
Country NO Norway
Listing OL ULTI

About Zelluna ASA

https://www.zelluna.com/

Zelluna ASA is a cell therapy company pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell immunotherapies for the treatment of solid cancers. The company's proprietary TCR-NK platform is designed to combine the high-precision targeting of TCRs with the potent, innate anti-tumor activity of NK cells. This approach aims to overcome the challenges associated with treating solid tumors. Zelluna is focused on creating a new generation of allogeneic, "off-the-shelf" cell therapies. The mission is to deliver transformative and potentially curative treatments for patients with advanced solid cancers, addressing a significant unmet medical need.

Recent filings

Filing Released Lang Actions
Ultimovacs ASA – Extraordinary General Meeting held on 11 November 2020
AGM Information Classification · 98% confidence The document explicitly states it concerns the 'Extraordinary General Meeting held on 11 November 2020' and confirms that 'All the matters on the agenda were approved.' It then lists the resulting composition of the board. This content directly relates to the proceedings and outcomes of a shareholder meeting. Although it mentions the minutes are enclosed, the primary purpose of this short announcement is to report the results and board changes following the meeting. This aligns best with the 'AGM Information' category (AGM-R), which covers presentations and materials shared during the Annual General Meeting (or, by extension, Extraordinary General Meetings, as it deals with meeting outcomes and board composition). It is not a DVA (Declaration of Voting Results) because it confirms approval rather than detailing the specific vote counts, and it is not an RPA because it is reporting the outcome, not just announcing the publication of a separate report.
2020-11-11 Norwegian
Ultimovacs ASA: Invitation to third quarter 2020 results webcast presentation
Report Publication Announcement Classification · 98% confidence The document is a short announcement inviting stakeholders to a webcast presentation for the third quarter 2020 results. It explicitly states that the 'report and presentation will be available on the company website from 08:00 CET the same day.' According to Rule #2 (The 'MENU VS MEAL' Rule), a short document announcing the publication of a report/presentation should be classified as a Report Publication Announcement (RPA), not the full report itself (which would likely be an IR or ER).
2020-11-09 English
Ultimovacs ASA – Disclosure of voting rights of Extraordinary General Meeting
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly discusses the 'Disclosure of voting rights' related to an 'Extraordinary General Meeting' (EGM). It details the number of shares represented by proxy by the Chairman of the Board for the upcoming vote. This directly relates to the official results or pre-meeting disclosure of voting power and rights associated with a general meeting. The most fitting category is 'Declaration of Voting Results & Voting Rights Announcements' (DVA), as it concerns the aggregation of voting rights prior to or immediately following a shareholder vote.
2020-11-03 English
Ultimovacs announces Acceptance of Publication in ‘Frontiers in Immunology’ featuring positive results from Phase I trial evaluating UV1 in Non-Small Cell Lung Cancer
Regulatory Filings Classification · 99% confidence The document is a press release from Ultimovacs announcing the 'Acceptance of Publication' of positive Phase I trial results in the journal 'Frontiers in Immunology'. It details clinical outcomes (survival rates, immune responses) and mentions ongoing Phase II studies. This is not a full regulatory report (like 10-K or IR), nor is it a formal earnings release (ER) or a transcript (CT). It is an announcement about scientific/clinical data dissemination. Since it is an announcement regarding clinical/scientific findings, and not a general regulatory filing (RNS) or a specific report type like an Audit Report (AR), the closest fit among the provided options that covers scientific/clinical updates or investor-focused presentations is Investor Presentation (IP), although this is a press release announcing a publication. Given the options, this type of announcement, which disseminates key clinical data to investors and the public, often falls under Investor Presentation (IP) or sometimes Regulatory Filing (RNS) if it were less specific. However, because it is a direct announcement of positive clinical data and publication acceptance, which is crucial for investor relations and strategy communication, IP is a strong candidate. If the document were the actual published paper or a detailed presentation deck, IP would be certain. As a press release announcing the publication, it functions as a high-level update for investors. Given the strong focus on clinical trial results and future development plans, I will classify it as an Investor Presentation (IP) as it serves that informational purpose, though RPA or RNS are also plausible fallbacks. Given the content is scientific results dissemination, IP is the most specific fit for conveying key data points to investors.
2020-11-02 English
Ultimovacs ASA: Notice of Extraordinary General Meeting on 11 November 2020 - proposed changes to the Board of Directors
Board/Management Information Classification · 99% confidence The document explicitly discusses recommendations by the Nomination Committee regarding the election of new Members of the Board of Directors, including biographical information for the nominees (Aitana Peire and Haakon Stenrød). This content directly relates to the composition and governance structure of the company's leadership. This aligns perfectly with the definition of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2020-10-21 English
Ultimovacs ASA: Notice of Extraordinary General Meeting on 11 November 2020 - proposed changes to the Board of Directors
Proxy Solicitation & Information Statement Classification · 98% confidence The document explicitly titles itself as a "Notice of Extraordinary General Meeting" and contains detailed instructions and forms for shareholders to register attendance or grant proxy votes for a meeting scheduled for November 11, 2020. This content is directly related to soliciting shareholder participation and providing necessary documentation for a general meeting, which aligns perfectly with the definition of Proxy Solicitation & Information Statement (PSI). While it relates to an AGM/EGM, the primary function of this document is the solicitation and proxy mechanism, not the final voting results (DVA) or the presentation materials (AGM-R). Since it is a notice/form for the meeting, PSI is the most accurate fit.
2020-10-21 Norwegian

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.